Gregory A Fonzo1, Vecheslav Federchenco2,3, Alba Lara2,3. 1. Department of Psychiatry, Dell Medical School, The University of Texas at Austin. 2. General Psychiatry Residency, Dell Medical School, The University of Texas at Austin. 3. Equal contributions to authorship.
Abstract
PURPOSE OF REVIEW: This review aims to synthesize existing research regarding the definition of treatment resistance in posttraumatic stress disorder (PTSD), predictors of treatment non-response to first-line interventions, and emerging second-line PTSD treatment options into an accessible resource for the practicing clinician. RECENT FINDINGS: The concept of treatment resistance in PTSD is currently poorly defined and operationalized. There are no well-established predictors of treatment non-response utilized in routine clinical care, but existing research identifies several potential candidate markers, including male gender, low social support, chronic and early life trauma exposure, comorbid psychiatric disorders, severe PTSD symptoms, and poor physical health. The most promising available treatment options for PTSD patients non-responsive to first-line psychotherapies and antidepressants include transcranial magnetic stimulation and ketamine infusion. Methylenedioxymethamphetamine-assisted psychotherapy also appears promising but is only available in a research context. These options require careful consideration of risks and benefits for a particular patient. SUMMARY: More research is required to develop a robust, clinically-useful definition of treatment resistance in PTSD; identify reliable, readily assessable, and generalizable predictors of PTSD treatment non-response; and implement measurement and prediction in clinical settings to identify individuals unlikely to respond to first-line treatments and direct them to appropriate second-line treatments.
PURPOSE OF REVIEW: This review aims to synthesize existing research regarding the definition of treatment resistance in posttraumatic stress disorder (PTSD), predictors of treatment non-response to first-line interventions, and emerging second-line PTSD treatment options into an accessible resource for the practicing clinician. RECENT FINDINGS: The concept of treatment resistance in PTSD is currently poorly defined and operationalized. There are no well-established predictors of treatment non-response utilized in routine clinical care, but existing research identifies several potential candidate markers, including male gender, low social support, chronic and early life trauma exposure, comorbid psychiatric disorders, severe PTSD symptoms, and poor physical health. The most promising available treatment options for PTSD patients non-responsive to first-line psychotherapies and antidepressants include transcranial magnetic stimulation and ketamine infusion. Methylenedioxymethamphetamine-assisted psychotherapy also appears promising but is only available in a research context. These options require careful consideration of risks and benefits for a particular patient. SUMMARY: More research is required to develop a robust, clinically-useful definition of treatment resistance in PTSD; identify reliable, readily assessable, and generalizable predictors of PTSD treatment non-response; and implement measurement and prediction in clinical settings to identify individuals unlikely to respond to first-line treatments and direct them to appropriate second-line treatments.
Authors: Rebecca K Sripada; Frederic C Blow; Sheila A M Rauch; Dara Ganoczy; Rani Hoff; Ilan Harpaz-Rotem; Kipling M Bohnert Journal: J Anxiety Disord Date: 2019-02-07
Authors: F Andrew Kozel; Michael A Motes; Nyaz Didehbani; Bambi DeLaRosa; Christina Bass; Caitlin D Schraufnagel; Penelope Jones; Cassie Rae Morgan; Jeffrey S Spence; Michael A Kraut; John Hart Journal: J Affect Disord Date: 2017-12-28 Impact factor: 4.839
Authors: Karen H Seal; Thomas J Metzler; Kristian S Gima; Daniel Bertenthal; Shira Maguen; Charles R Marmar Journal: Am J Public Health Date: 2009-07-16 Impact factor: 9.308
Authors: Naomi M Simon; Kathryn M Connor; Ariel J Lang; Sheila Rauch; Stan Krulewicz; Richard T LeBeau; Jonathan R T Davidson; Murray B Stein; Michael W Otto; Edna B Foa; Mark H Pollack Journal: J Clin Psychiatry Date: 2008-03 Impact factor: 4.384